Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
Immunovant CEO Peter Salzmann sold 4,807 shares of common stock on April 9, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On April 9, 2024, Peter Salzmann, the CEO of Immunovant, Inc., sold 4,807 shares of common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of 8,281 restricted stock units (RSUs) on April 1, 2024.
- The shares were sold at a weighted average price of $31.18, with individual transactions ranging from $30.73 to $31.45 per share.
- Following the transaction, Salzmann directly owns 1,086,958 shares of Immunovant common stock.
- The sale was mandated by Immunovant's policy requiring tax obligations to be met through a 'sell to cover' transaction.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell to cover) related to executive compensation. It doesn't inherently indicate positive or negative sentiment regarding the company's performance or future prospects.
Industry Context
Sales of shares to cover tax obligations upon RSU vesting are a common practice among executives of publicly traded companies. This transaction reflects a standard procedure for managing equity compensation.
Key Dates
| Date | Description |
|---|---|
| 2021/03/19 | Grant date of 132,500 restricted stock units (RSUs). |
| 2024/04/01 | Vesting date of 8,281 RSUs. |
| 2024/04/09 | Date of stock sale to cover tax obligations. |
| 2024/04/10 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.